First, although we performed the assay system using multiparametric flow cytometry after CTC enrichment in patients with HCC, only 19 patients received atezolizumab and bevacizumab treatment, which is a small fraction to draw definitive conclusions about the usefulness of CD90(+) and EpCAM(+) CTCs as predictive biomarkers of response to therapy. Here, THY1 is linked to hepatocellular carcinoma.